Dinutuximab beta in high-risk neuroblastoma: a profile of its use

McKeage, Kate; Lyseng‐Williamson, Katherine A.

doi:10.1007/s40267-018-0522-2

Cited by 2 publications

(3 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pharmacokinetic data were accessible from three clinical studies: APN311-101, -202 and -303 (see Table 1 ) [ 9 , 17 , 18 ]. In these studies [ 9 , 18 ], maximum levels were generally attained at the end of the 10-day infusion, and the approximated half-life ( t ½ ) was around 190 h [ 9 , 18 ].…”

Section: Dinutuximab Betamentioning

confidence: 99%

Recent Evidence-Based Clinical Guide for the Use of Dinutuximab Beta in Pediatric Patients with Neuroblastoma

et al. 2022

View full text Add to dashboard Cite

The anti-GD2 antibody dinutuximab beta (Qarziba ® ) has been added to the present standard of care for patients with highrisk neuroblastoma in Europe based on the positive results obtained in different studies. In both the first-line and relapsed/ refractory settings, treatment with dinutuximab beta attains objective clinical responses in children with high-risk neuroblastoma. Its incorporation has changed the outcome for these patients and optimized management should be guaranteed to minimize possible adverse effects. Most prevalent adverse events include pain, allergic reactions, fever and capillary leak syndrome. There are still no evidence-based clinical guidelines that include the latest published evidence to optimize its use, as it depends on the experience gained in each referral center. Topics such as the mode of preparation and administration, the concomitant use of interleukin-2, the recommended pediatric age and dose for its use, or the adequate management of possible toxicities are important aspects to review. The objective of this article was to update the clinical guide to management with dinutuximab beta of children with neuroblastoma based on the most recent published evidence and our own experience in clinical practice.

show abstract

Section: Dinutuximab Betamentioning

confidence: 99%

Recent Evidence-Based Clinical Guide for the Use of Dinutuximab Beta in Pediatric Patients with Neuroblastoma

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Anti‐GD2 mAbs approved for clinical use include dinutuximab (Unituxin®), dinutuximab beta (Qarziba®) and naxitamab (Danyelza®) 5–7 . Dinutuximab (ch14.18) and dinutuximab beta (ch14.18/CHO) are both human/mouse chimeric mAbs 16 . While dinutuximab is produced using mouse SP2/0 cells, dinutuximab beta is produced using Chinese hamster ovary cells 16 .…”

Section: Introductionmentioning

confidence: 99%

“…Dinutuximab (ch14.18) and dinutuximab beta (ch14.18/CHO) are both human/mouse chimeric mAbs 16 . While dinutuximab is produced using mouse SP2/0 cells, dinutuximab beta is produced using Chinese hamster ovary cells 16 . Naxitamab (hu3F8) is a humanized mAb.…”

Section: Introductionmentioning

confidence: 99%

GM‐CSF, G‐CSF or no cytokine therapy with anti‐GD2 immunotherapy for high‐risk neuroblastoma

Mora,

Modak,

Kinsey

et al. 2023

Intl Journal of Cancer

View full text Add to dashboard Cite

Colony‐stimulating factors have been shown to improve anti‐disialoganglioside 2 (anti‐GD2) monoclonal antibody response in high‐risk neuroblastoma by enhancing antibody‐dependent cell‐mediated cytotoxicity (ADCC). A substantial amount of research has focused on recombinant human granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) as an adjuvant to anti‐GD2 monoclonal antibodies. There may be a disparity in care among patients as access to GM‐CSF therapy and anti‐GD2 monoclonal antibodies is not uniform. Only select countries have approved these agents for use, and even with regulatory approvals, access to these agents can be complex and cost prohibitive. This comprehensive review summarizes clinical data regarding efficacy and safety of GM‐CSF, recombinant human granulocyte colony‐stimulating factor (G‐CSF) or no cytokine in combination with anti‐GD2 monoclonal antibodies (ie, dinutuximab, dinutuximab beta or naxitamab) for immunotherapy of patients with high‐risk neuroblastoma. A substantial body of clinical data support the immunotherapy combination of anti‐GD2 monoclonal antibodies and GM‐CSF. In contrast, clinical data supporting the use of G‐CSF are limited. No formal comparison between GM‐CSF, G‐CSF and no cytokine has been identified. The treatment of high‐risk neuroblastoma with anti‐GD2 therapy plus GM‐CSF is well established. Suboptimal efficacy outcomes with G‐CSF raise concerns about its suitability as an alternative to GM‐CSF as an adjuvant in immunotherapy for patients with high‐risk neuroblastoma. While programs exist to facilitate obtaining GM‐CSF and anti‐GD2 monoclonal antibodies in regions where they are not commercially available, continued work is needed to ensure equitable therapeutic options are available globally.

show abstract

Dinutuximab beta in high-risk neuroblastoma: a profile of its use

Cited by 2 publications

References 11 publications

Recent Evidence-Based Clinical Guide for the Use of Dinutuximab Beta in Pediatric Patients with Neuroblastoma

Recent Evidence-Based Clinical Guide for the Use of Dinutuximab Beta in Pediatric Patients with Neuroblastoma

GM‐CSF, G‐CSF or no cytokine therapy with anti‐GD2 immunotherapy for high‐risk neuroblastoma

Contact Info

Product

Resources

About